Design of cancer vaccines based on the use of non-natural glycopeptides with β-amino acids

  1. Oscar Suárez García 1
  2. Alberto Avenoza 1
  3. Jesús M. Peregrina 1
  4. Marimar Zurbano 1
  5. Francisco Corzana 1
  6. Jesús H. Busto 1
  7. Fayna García-Martín 1
  1. 1 Universidad de La Rioja
    info

    Universidad de La Rioja

    Logroño, España

    ROR https://ror.org/0553yr311

Aktak:
XVII Simposio de Investigadores Jóvenes RSEQ. Libro de resúmenes

Argitalpen urtea: 2021

Biltzarra: XVII Simposio de Investigadores Jóvenes RSEQ, 23-26 de noviembre de 2021, Alcalá de Henares

Mota: Biltzar ekarpena

beta Ver similares en nube de resultados
GOOGLE SCHOLAR lock_openSarbide irekia editor
Gordailu instituzionala: lock_openSarbide irekia Editor

Laburpena

The Tn antigen (GalNAc-α-1-O-Thr) is a well-known tumor-associated carbohydratedeterminant. The use of glycopeptides that incorporate this structure (such as the mucin 1, MUC1)has become a promising research niche owing to their potential use as cancer vaccines [1].Nevertheless, the current vaccine candidates have, in general, weak immune response in vivo dueto their poor stability and inmunogenicity [2]. To tackle this issue, we will modify several residuesin the peptide sequence of MUC1 by unnatural amino acids and conjugate them to silicananoparticles (SiNP), which have luminescent properties and low toxicity.In a first approximation, several natural amino acids of MUC1 will be replaced by their β-aminoacids analogous [3] and the arginine residue by another surrogate bearing a fluorine atom.In this communication, the synthetic routes, and challenges in obtaining the surrogates will bedescribed. A library of glycopeptides containing β-amino acids and the affinity of theglycopeptides for the SM3 antibody will be presented. These preliminary results will be discussedalong with future prospects.